Drugs / 4SCAR-GD2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04430595 | Jun 2026 → Dec 2029 expected | breast cancer | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02992210 | May 2025 → Jun 2028 expected | cancer | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR-GD2 | “Infusion of 4SCAR-GD2, -Her2 and -CD44v6 CAR-T cells” NCT04430595 ↗ |
| Action | Deplete | “The 4SCAR-GD2-modified T cells can recognize and kill tumor cells” NCT02992210 ↗ |
| Modality | Cell therapy | “T cells genetically modified” NCT02992210 ↗ |
| Route | Other | “Infusion of 4SCAR-GD2, -Her2 and -CD44v6 CAR-T cells” NCT04430595 ↗ |